Abstract library

56 results for "Paraganglioma".
#124 Management and outcomes of malignant paragangliomas and phaeochromocytomas
Introduction: Chromaffin-cell tumors include phaeochromocytomas and paragangliomas, represent a rare group of neuroendocrine tumors and are located in adrenal medulla or extra-adrenal sites, respectively. Ten percent of phaeochromocytomas and 15-35% of paragangliomas are malignant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Christos Toumpanakis
#145 Paragangliomas: a series of five cases
Introduction: Paraganglioma is a rare extraadrenal neuroendocrine tumor, composed of chromaffin cells and arising from the neural crest. The head, neck, and retroperitoneum are the most common sites for paraganglioma.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Assoc. Professor Catalina Poiana
Authors: Poiana C, Carsote M, Paun D, Hortopan D, ...
#2149 Symptomatic Hypothalamic-Pituitary Metastases Disclosing Malignant Paraganglioma
Introduction: A paraganglioma is a rare tumor composed of chromaffin cells. Malignant paraganglioma is a very rare presentation diagnosed by local recurrence after total resection of the primary mass or findings of distant metastasis. We report a case of a 34-year-old women with a Malignant paraganglioma presneting with visual loss and hypopituitarism resulting from metastasis to the pituitary area. The diagnosis of malignant paraganglioma was based on loco-regional and distant metastasis
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Aicha Bengueddach
#22 A Case Illustrative of Phenotypic Heterogeneity and Challenges in the Management of Paraganglioma
Introduction: Paragangliomas (PGLs) are extra-adrenal, usually benign, highly vascularized tumors that originate from neural-crest-derived chromaffin cells. These tumors are subdivided as either sympathetic or parasympathetic, depending on their location and catecholamine production. Sympathetic PGLs are situated along the abdominal sympathetic trunk and usually produce catecholamines, whereas parasympathetic PGLs are located in the head and neck, and these usually do not produce catecholamines. PGLs may present as sporadic or inherited tumor syndrome, including MEN 2, with RET germline mutations, von Hippel-Lindau (VHL) disease due to germline mutations in VHL gene, and pheochromocytoma-PGL syndrome. The latter is frequently a hereditary condition and is caused by germline mutations in the SDHB, SDHC, or SDHC genes. Patients with familial PGLs may present at a younger age, often as multifocal tumors, with an increased risk of recurrence and a higher frequency of malignancy in those with SDHB mutations. SDH mutations induce angiogenesis and tumorogenesis through the inhibition of hypoxia-inducible factors (HIF)-propyl hyroxylase. A younger age at onset, malignancy, and a positive family history are clinical parameters of high specificity, but low sensitivity for diagnosis. Genetic analysis for mutations in SDH genes for the patient and family members, and surveillance for the affected patient and family members, are necessary where there are no clear clinical or family indicators for the syndrome. We present a case of a large abdominal malignant PGL in a 20-year-old pt. that went on without clinical detection for at least three years.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohammed Ahmed
#925 Negative Urinary Fractionated Metanephrines and Elevated Urinary Vanillylmandelic Acid in a Patient with a Sympathetic Paravesical Paraganglioma
Introduction: Paragangliomas have hereditary and sporadic presentations.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Edwin A Wandurraga
Authors: Wandurraga E A, Marín L F, ...
#1173 Investigation of the Effects of Sunitinib on Pheochromocytoma and Paraganglioma Primary Cultures
Introduction: The main treatment for Pheochromocytoma and Paraganglioma is surgery. However these tumors are highly vascularized, suggesting the possible role for anti-angiogenic agents in the medical therapy. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor (TKI), mainly described to inhibit VEGFR
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Teresa Gagliano
Authors: Bellio M, Gagliano T, Feo C, Balboni F, ...
#1347 Evaluation of the Somatostatin, CXCR4 Chemokine and Endothelin A Receptor Expression in a Large Series of Paragangliomas
Introduction: Paragangliomas are predominantly benign tumors, but in some cases invasive growth and also metastasis is observed. Given the limited number of nonsurgical treatment options, novel target structures for diagnostics and therapy of this tumor entity are urgently needed.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Prof. Amelie Lupp
#1640 SDHB Mutation in a Young Patient with a Metastatic Paraganglioma of the Urinary Bladder
Introduction: Paragangliomas are rare tumors that arise from the sympathetic and parasympathetic ganglia that can possess an inherited trait.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Ioana Maria Lambrescu
Authors: Lambrescu I M, Cima L, Leca B, Martin S, ...
#2054 Mediastinal Paraganglioma - A Challenge from the Surgical Point of View
Introduction: Mediastinal paraganglima are extremely rare neuroendocrine tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Katarzyna Blazejczyk
Authors: Blazejczyk K, Leschber G, ...
#566 A Case Report of a Patient with Metastatic Cervical Paraganglioma Responding to the Tyrosine Kinase Inhibitor Sunitinib
Introduction: Paragangliomas are rare neuroendocrine neoplasms that arise from neural crest cells, and are associated with increased expression of angiogenic growth factors. There have been isolated case reports describing potential efficacy with Sunitinib, a tyrosine kinase inhibitor.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Olga Oikonomidou